| Literature DB >> 35840705 |
Ruth Ann Marrie1,2, Mark Allegretta3, Lisa F Barcellos4,5, Bruce Bebo3, Peter A Calabresi6, Jorge Correale7, Benjamin Davis8, Philip L De Jager9, Christiane Gasperi10, Carla Greenbaum11, Anne Helme12, Bernhard Hemmer10,13, Pamela Kanellis8, Walter Kostich3, Douglas Landsman3, Christine Lebrun-Frenay14, Naila Makhani15, Kassandra L Munger16, Darin T Okuda17, Daniel Ontaneda18, Ronald B Postuma19, Jacqueline A Quandt20, Sharon Roman21, Shiv Saidha22, Maria Pia Sormani23, Jon Strum24, Pamela Valentine8, Clare Walton25, Kathleen M Zackowski3, Yinshan Zhao26, Helen Tremlett26.
Abstract
A prodrome is an early set of signs or symptoms that indicate the onset of a disease before more typical symptoms develop. Prodromal stages are well recognized in some neurological and immune-mediated diseases such as Parkinson disease, schizophrenia, type 1 diabetes mellitus and rheumatoid arthritis. Emerging evidence indicates that a prodromal stage exists in multiple sclerosis (MS), raising the possibility of intervention at this stage to delay or prevent the development of classical MS. However, much remains unclear about the prodromal stage of MS and considerable research is needed to fully characterize the prodrome and develop standardized criteria to reliably identify individuals with prodromal MS who are at high risk of progressing to a diagnosis of MS. In this Roadmap, we draw on work in other diseases to propose a disease framework for MS that incorporates the prodromal stage, and set out key steps and considerations needed in future research to fully characterize the MS prodrome, identify early disease markers and develop standardized criteria that will enable reliable identification of individuals with prodromal MS, thereby facilitating trials of interventions to slow or stop progression beyond the prodrome.Entities:
Mesh:
Year: 2022 PMID: 35840705 DOI: 10.1038/s41582-022-00686-x
Source DB: PubMed Journal: Nat Rev Neurol ISSN: 1759-4758 Impact factor: 44.711